Abstract Details

Title Real-World Effectiveness of Ubrogepant for the Acute Treatment of Migraine When Used in Combination With an Anti-Calcitonin Gene–Related Peptide Monoclonal Antibody Preventive: Results From the COURAGE Study

Topic Headache

Presentation(s) P10 - Poster Session 10 (8:00 AM-9:00 AM)

Poster/Presentation
Number 15-003

Background Ubrogepant is an oral CGRP receptor antagonist approved for the acute treatment of migraine. Real-world treatment effectiveness and satisfaction when used in combination with an anti-CGRP mAb preventive is unknown.

Objective To evaluate the effectiveness of ubrogepant when used in combination with an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) preventive.

Design/Methods

This prospective, observational study evaluated real-world effectiveness of ubrogepant (50 or 100mg) for acute treatment when taken with an anti-CGRP mAb, onabotulinumtoxinA, or both using data collected via the Migraine Buddy application. Eligible adults reported ≥3 migraine attacks in the last 30 days, had treated ≥3 prior attacks with ubrogepant, and were concurrently taking an anti-CGRP mAb, onabotulinumtoxinA, or both for migraine prevention. Over 30 days, participants continued to treat attacks of any pain intensity with their prescribed dose of ubrogepant. Self-reported assessments included: meaningful pain relief (MPR; reduction of headache pain to a meaningful degree or remaining pain free if none was reported at ubrogepant dosing) and return to normal function (RNF) after dosing. Results from the first ubrogepant-treated attack and first 10 ubrogepant-treated attacks in the ubrogepant+CGRP mAb group are reported.

Results A total of 245 participants reported using ubrogepant as acute treatment with an anti-CGRP mAb, with 1153 ubrogepant-treated attacks included in the analysis. For the first treated attack, MPR was achieved in 61.6% and 80.4% of ubrogepant-treated participants at 2- and 4-hours post-dose, respectively. RNF was achieved by 34.7% and 55.5% at 2- and 4-hours post-dose. For the 10 ubrogepant-treated attacks, MPR was achieved in 51.3% and 73.5% of ubrogepant-treated attacks at 2- and 4-hours post-dose, respectively. RNF was achieved by 32.2% and 53.2% at 2- and 4-hours post-dose.

Conclusions This analysis suggests that ubrogepant has treatment benefit when used in combination with an anti-CGRP mAb. These results can aid clinicians in optimizing migraine management in their practice.

Authors/Disclosures
Aubrey Adams, PhD PRESENTER	Dr. Manack Adams has received personal compensation for serving as an employee of Abbvie. Dr. Manack Adams has stock in Abbvie.
Janette Contreras-De Lama	Janette Contreras-De Lama has received personal compensation for serving as an employee of AbbVie. Janette Contreras-De Lama has stock in AbbVie.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Francois Cadiou, MBA (Healint)	Mr. Cadiou has received personal compensation for serving as an employee of Healint.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. Dr. Lipton has stock in Axon. Dr. Lipton has stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.